[go: up one dir, main page]

UA91190C2 - Контроль прорывных кровотечений при пролонгированном режиме приема гормональных контрацептивов - Google Patents

Контроль прорывных кровотечений при пролонгированном режиме приема гормональных контрацептивов

Info

Publication number
UA91190C2
UA91190C2 UAA200612358A UAA200612358A UA91190C2 UA 91190 C2 UA91190 C2 UA 91190C2 UA A200612358 A UAA200612358 A UA A200612358A UA A200612358 A UAA200612358 A UA A200612358A UA 91190 C2 UA91190 C2 UA 91190C2
Authority
UA
Ukraine
Prior art keywords
management
hormonal contraceptive
breakthrough bleeding
contraceptive regimens
extended
Prior art date
Application number
UAA200612358A
Other languages
English (en)
Ukrainian (uk)
Inventor
Андреас Заксе
Патрісіа Джей. Сулак
Original Assignee
Шерінг Акцієнгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шерінг Акцієнгезельшафт filed Critical Шерінг Акцієнгезельшафт
Publication of UA91190C2 publication Critical patent/UA91190C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение касается способа женской гормональной контрацепции, который включает монофазное непрерывное применение активного препарата с содержанием эстрогена в количестве, эквивалентном от 5 до < 30 мкг этинилэстрадиола в сутки, и прогестина в контрацептивном количестве на протяжении первого минимального периода, продолжительность которого определяется по желанию женщины и длится до наступления кровотечения, которое неприемлемо для нее, после которого она инициирует перерыв в 1-6 дней в приеме указанного препарата, и в котором за указанным перерывом идет по крайней мере один дальнейший цикл приема, продолжительностью не менее первого минимального периода.
UAA200612358A 2004-04-30 2005-04-29 Контроль прорывных кровотечений при пролонгированном режиме приема гормональных контрацептивов UA91190C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56644304P 2004-04-30 2004-04-30

Publications (1)

Publication Number Publication Date
UA91190C2 true UA91190C2 (ru) 2010-07-12

Family

ID=38019305

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200612358A UA91190C2 (ru) 2004-04-30 2005-04-29 Контроль прорывных кровотечений при пролонгированном режиме приема гормональных контрацептивов

Country Status (4)

Country Link
CN (2) CN1950092A (ru)
GT (1) GT200500099A (ru)
UA (1) UA91190C2 (ru)
ZA (1) ZA200609988B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2989975C (en) * 2015-06-23 2021-10-12 Laboratorios Leon Farma Sa Drospirenone-based contraceptive for a female patient affected with excess weight

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive

Also Published As

Publication number Publication date
GT200500099A (es) 2006-05-05
CN1950092A (zh) 2007-04-18
ZA200609988B (en) 2008-07-30
CN107875388A (zh) 2018-04-06

Similar Documents

Publication Publication Date Title
TW200603781A (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens
DK1773296T3 (da) Farmaceutisk vaginalgel indeholdende tenofovir
ZA200704434B (en) Manifold for use in medicament dispenser
IL183101A (en) Use of tetrahydrocannabivarin in drug production
TW200744667A (en) Foamable suspension gel
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
EP1762213A4 (en) A LOCKED BODY CONTAINING MEDICAMENT
AP2004003046A0 (en) Dosage regimen and pharmaceutical composition for emergency contraception.
IL181445A0 (en) Use of (halobenzyloxy)benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium selective modulators
EP1779831A4 (en) SEALED ARTICLE WITH THE MEDICAMENT STORED IN IT
CL2007001961A1 (es) Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo.
IL180899A0 (en) Pharmaceutical composition comprising drospirenone and ethynylestradiol
ZA200701443B (en) Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
UA91190C2 (ru) Контроль прорывных кровотечений при пролонгированном режиме приема гормональных контрацептивов
EP2234491A4 (en) DOSAGE SCHEMES AND PHARMACEUTICAL COMPOSITIONS AND PACKAGING FOR EMERGENCY CONTRACEPTION
JO3731B1 (ar) تدبير نزيف مفاجئ في انظمة موانع حمل هرمونية
AU2003215767A8 (en) Devices for use in medicine
CU20060204A7 (es) Tratamiento de la hemorragia de disrupción en regímenes anticonceptivos extendidos
TW200634019A (en) Thienoisoquinoline-phenylsulfonamides and their use as er-nfkb inhibitors
GB0415154D0 (en) Transit and display packaging
GB0406014D0 (en) Pharmaceutical composition and use
GB0209874D0 (en) Devices for use in medicine
HU0500490D0 (en) Intra-uterine contraceptive
GB0406678D0 (en) Hygenic packaging
RU2006106570A (ru) Спермицидное средство